D. Sherstnev

Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy

S. Voloshin, I. Poddubnaya, E. Nesterova, 2021, Journal of Modern Oncology.

Bleeding rate reduction in children with hemophilia A and inhibitors treated with emicizumab in the real-world clinical setting

P. Zharkov, T. Shelekhova, T. Andreeva, 2022, Pediatric Hematology/Oncology and Immunopathology.

The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin’s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice

M. V. Volkov, T. Shelekhova, K. Lepik, 2022, Clinical oncohematology.